MicroRNAs (miRNAs) serve as critical regulators of gene expression. However, their binding to target genes can be influenced by genetic variability within the miRNA-target interaction (MTI) sites. We performed an in silico sequence reanalysis to identify novel sequence variants within MTIs with potential functional impacts. A literature search of the PubMed and the Web of Science spanning the years 2008 to April 2018 identified 240 articles reporting MTIs in humans. Sequence reanalysis of reported MTI regions was performed using the Ensembl browser. We found 76 sequence variants within 23 MTIs. We present description of MTIs wherein sequence variants are present within both the mature miRNA seed region and the miRNA target, which we termed miR-gene-target-single nucleotide polymorphism (miR-GenTar-SNP). To the best of our knowledge, this is the first report on copresence of sequence variants within both miRNA gene and the target site. In the course our analyses, the need for extension of current terminology emerged and therefore, novel terminology was introduced: miR-indel, miR-double nucleotide polymorphism (DNP), miR-TS-indel, and miR-TS-DNP. Identification of novel MTI sequence variants is a hitherto understudied, but critical dimension in understanding the complexity of interactions and gene deregulation in various complex diseases. Because such variations might profoundly affect miRNA function, they should be taken into consideration in future research that depends on “variability science” such as precision medicine, human genetics, and genomics in the study of complex diseases. The findings presented herein offer a baseline for further systematic reanalysis of all reported MTIs in human and other species.
Get full access to this article
View all access options for this article.
References
1.
AbdelmohsenK, HutchisonER, LeeEK, et al. (2010). miR-375 inhibits differentiation of neurites by lowering HuD levels. Mol Cell Biol, 30, 4197–4210.
2.
AcunzoM, RomanoG, WernickeD, et al. (2015). MicroRNA and cancer—a brief overview. Adv Biol Regul, 57, 1–9.
3.
AgarwalV, BellGW, NamJW, et al. (2015). Predicting effective microRNA target sites in mammalian mRNAs. Elife, 4, e05005.
4.
AutonA, BrooksLD, DurbinRM, et al. (2015). A global reference for human genetic variation. Nature, 526, 68–74.
5.
BaoM, SongY, XiaJ, et al. (2018). miR-1269 promotes cell survival and proliferation by targeting tp53 and caspase-9 in lung cancer. Onco Targets Ther, 11, 1721–1732.
BhattacharyaA, ZiebarthJD, and CuiY. (2014). PolymiRTS database 3.0: Linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res, 42, D86–D91.
8.
CalinGA, SevignaniC, DumitruCD, et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A, 101, 2999–3004.
9.
CardDA, HebbarPB, LiL, et al. (2008). Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol, 28, 6426–6438.
10.
ChenK, SongF, CalinGA, et al. (2008). Polymorphisms in microRNA targets: A gold mine for molecular epidemiology. Carcinogenesis, 29, 1306–1311.
11.
ChouCH, ChangNW, ShresthaS, et al. (2016). miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res, 44, D239–D247.
12.
DesvignesT, BatzelP, BerezikovE, et al. (2015). miRNA nomenclature: A view incorporating genetic origins, biosynthetic pathways, and sequence variants. Trends Genet, 31, 613–626.
13.
DossCGP, RajithB, SeelanTSJ, et al. (2013). In silico profiling of miRNAs and their target polymorphisms in leukemia associated genes. Egypt J Med Hum Genet, 14, 221–225.
14.
Dzikiewicz-KrawczykA, MaciejaA, MałyE, et al. (2014). Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding. J Hematol Oncol, 7, 43.
15.
FuYR, LiuXJ, LiXJ, et al. (2015). MicroRNA miR-21 attenuates human cytomegalovirus replication in neural cells by targeting Cdc25a. J Virol, 89, 1070–1082.
16.
GeorgesM, CoppietersW, and CharlierC. (2007). Polymorphic miRNA-mediated gene regulation: Contribution to phenotypic variation and disease. Curr Opin Genet Dev, 17, 166–176.
17.
GhaediH, BastamiM, JahaniMM, et al. (2016). A bioinformatics approach to the identification of variants associated with type 1 and type 2 diabetes mellitus that reside in functionally validated miRNAs binding sites. Biochem Genet, 54, 211–221.
18.
IorioMV, PiovanC, and CroceCM. (2010). Interplay between microRNAs and the epigenetic machinery: An intricate network. Biochim Biophys Acta, 1799, 694–701.
19.
ItohH, ShimizuW, HayashiK, et al. (2010). Long QT syndrome with compound mutations is associated with a more severe phenotype: A Japanese multicenter study. Heart Rhythm, 7, 1411–1418.
20.
Jevsinek SkokD, GodnicI, ZorcM, et al. (2013). Genome-wide in silico screening for microRNA genetic variability in livestock species. Anim Genet, 44, 669–677.
21.
KellyTJ, SouzaAL, ClishCB, et al. (2011). A hypoxia-induced positive feedback loop promotes hypoxia-inducible factor 1alpha stability through miR-210 suppression of glycerol-3-phosphate dehydrogenase 1-like. Mol Cell Biol, 31, 2696–2706.
KunejT, GodnicI, HorvatS, et al. (2012). Cross talk between microRNA and coding cancer genes. Cancer J, 18, 223–231.
24.
LandiD, GemignaniF, BaraleR, et al. (2008). A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol, 27, 35–43.
25.
LekM, KarczewskiKJ, MinikelEV, et al. (2016). Analysis of protein-coding genetic variation in 60,706 humans. Nature, 536, 285–291.
26.
LimLP, LauNC, Garrett-EngeleP, et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433, 769–773.
27.
LinXT, ZhengXB, FanDJ, et al. (2018). MicroRNA-143 targets ATG2B to inhibit autophagy and increase inflammatory responses in Crohn's disease. Inflamm Bowel Dis, 24, 781–791.
28.
LiuW, KangL, HanJ, et al. (2018a). miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. Onco Targets Ther, 11, 1643–1653.
29.
LiuX, WangL, ChiH, et al. (2018b). The SNP rs915014 in MTHFR regulated by MiRNA associates with atherosclerosis. Cell Physiol Biochem, 45, 1149–1155.
30.
MishraPJ, and BertinoJR. (2009). MicroRNA polymorphisms: The future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics, 10, 399–416.
31.
MukherjeeA, Di BisceglieAM, and RayRB. (2015). Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J Virol, 89, 3356–3365.
NicolosoMS, SunH, SpizzoR, et al. (2010). Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res, 70, 2789–2798.
34.
NiuT, LiuN, ZhaoM, et al. (2015). Identification of a novel FGFRL1 microRNA target site polymorphism for bone mineral density in meta-analyses of genome-wide association studies. Hum Mol Genet, 24, 4710–4727.
35.
NykampK, AndersonM, PowersM, et al. (2017). Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med, 19, 1105–1117.
36.
ObsteterJ, DovcP, and KunejT. (2015). Genetic variability of microRNA regulome in human. Mol Genet Genomic Med, 3, 30–39.
37.
PiletičK, and KunejT. (2016) MicroRNA epigenetic signatures in human disease. Arch Toxicol, 90, 2405–2419.
38.
PiletičK, and KunejT. (2017). Minimal standards for reporting microRNA: Target interactions. OMICS, 21, 197–206.
39.
PoppNA, YuD, GreenB, et al. (2016). Functional single nucleotide polymorphism in IL-17A 3′ untranslated region is targeted by miR-4480 in vitro and may be associated with age-related macular degeneration. Environ Mol Mutagen, 57, 58–64.
40.
RichardsonK, NettletonJA, RotllanN, et al. (2013). Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site. Am J Hum Genet, 92, 5–14.
41.
SalzmanDW, and WeidhaasJB. (2013). SNPing cancer in the bud: MicroRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther, 137, 55–63.
42.
SaundersMA, LiangH, and LiWH. (2007). Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A, 104, 3300–3305.
43.
SethupathyP, and CollinsFS. (2008). MicroRNA target site polymorphisms and human disease. Trends Genet, 24, 489–497.
44.
SlemcL, and KunejT. (2016). Transcription factor HIF1A: Downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites and initiative for standardization of reporting in scientific literature. Tumor Biol, 37, 14851–14861.
45.
SongS, ChenD, LuJ, et al. (2011). NFκB1 and NFκBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS One, 6, e21726.
46.
StensonPD, MortM, BallEV, et al. (2017). The human gene mutation database: Towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet, 136, 665–677.
47.
SureshPS, VenkateshT, and TsutsumiR. (2016). In silico analysis of polymorphisms in microRNAs that target genes affecting aerobic glycolysis. Ann Transl Med, 4, 69.
48.
WangC, ZhangX, and ZhangC. (2017). MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth. Pathol Res Pract, 213, 389–393.
49.
WangZ, ChenS, ZhuM, et al. (2018). Functional SNP in the 3′UTR of PON1 is associated with the risk of calcific aortic valve stenosis via MiR-616. Cell Physiol Biochem, 45, 1390–1398.
50.
WareJS, WalshR, CunninghamF, et al. (2012). Paralogous annotation of disease-causing variants in long QT syndrome genes. Hum Mutat, 33, 1188–1191.
51.
YangSF, LiuYF, ChengCW, et al. (2017). Impact of microRNA-34a and polymorphism of its target gene CA9 on susceptibility to uterine cervical cancer. Oncotarget, 8, 77860–77871.
YatesB, BraschiB, GrayKA, et al. (2017). Genenames.org: The HGNC and VGNC resources in 2017. Nucleic Acids Res, 45, D619–D625.
54.
ZhangX, YoonJY, MorleyM, et al. (2018). A common variant alters SCN5A-miR-24 interaction and associates with heart failure mortality. J Clin Invest, 128, 1154–1163.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
